Economic evaluation of the 21-gene signature (Oncotype DX ®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)

Breast Cancer Research and Treatment

Volumn 127, Issue 3, 2011, Pages 739-749

  Kondo, Masahide ^a   Hoshi, Shu Ling ^a   Yamanaka, Takeharu ^b   Ishiguro, Hiroshi ^c   Toi, Masakazu ^d  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

21 Gene signature; Adjuvant therapy; Breast cancer; Cost effectiveness; Gene diagnosis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; HORMONE RECEPTOR; METHOTREXATE; PYRIMIDINE; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DIAGNOSTIC TEST; DISEASE FREE SURVIVAL; DRUG COST; DRUG RESPONSE; ECONOMIC EVALUATION; HIDDEN MARKOV MODEL; HUMAN; JAPAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; SENSITIVITY ANALYSIS; SOCIAL INSURANCE; VALIDATION STUDY; VOMITING;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; JAPAN; LYMPHATIC METASTASIS; NEOPLASM STAGING; QUALITY-ADJUSTED LIFE YEARS; REAGENT KITS, DIAGNOSTIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 79958265641     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1243-y     Document Type: Article

References (33)

1. The Japanese Breast Cancer Society (2009) Zenkoku nyugan kanjya touroku chousa houkoku-zanteiban-dai 38 gou 2007 nenji shourei (National breast cancer registry report-provisional edition-No. 38 2007 cases). The Japanese Breast Cancer Society, Tokyo
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and endocrine therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
3. A Goldhirsch JN Ingle RD Gelber AS Coates B Thürlimann HJ Senn Panel members 2009 Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer Ann Oncol 20 8 1319 1329 19535820 10.1093/annonc/mdp322 1:STN:280: DC%2BD1Mrjtlyhug%3D%3D
4. S Paik S Shak G Tang C Kim J Baker M Cronin FL Baehner MG Walker D Watson T Park W Hiller ER Fisher DL Wickerham J Bryant N Wolmark 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 27 2817 2826 15591335 10.1056/NEJMoa041588 1:CAS:528: DC%2BD2MXhslymsw%3D%3D (Pubitemid 40051905)
5. S Paik G Tang S Shak C Kim J Baker W Kim M Cronin FL Baehner D Watson J Bryant JP Costantino CE Geyer Jr DL Wickerham N Wolmark 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 23 3726 3734 16720680 10.1200/JCO.2005.04.7985 1:CAS:528:DC%2BD28XpsVaqsrs%3D (Pubitemid 46622311)
6. LA Habel S Shak MK Jacobs A Capra C Alexander M Pho J Baker M Walker D Watson J Hackett NT Blick D Greenberg L Fehrenbacher B Langholz CP Quesenberry 2006 A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Res 8 3 R25 16737553 10.1186/bcr1412 (Pubitemid 43827376)
7. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical Oncology (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287-5312
8. TM Breast Cancer V.2.2008
9. KS Albain WE Barlow S Shak GN Hortobagyi RB Livingston IT Yeh P Ravdin R Bugarini FL Baehner NE Davidson GW Sledge EP Winer C Hudis JN Ingle EA Perez KI Pritchard L Shepherd JR Gralow C Yoshizawa DC Allred CK Osborne DF Hayes Breast Cancer Intergroup of North America 2010 Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, estrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 1 55 65 20005174 10.1016/S1470-2045(09)70314-6 1:CAS:528:DC%2BC3cXjslKrtQ%3D%3D
10. M Dowsett J Cuzick C Wale J Forbes EA Mallon J Salter E Quinn A Dunbier M Baum A Buzdar A Howell R Bugarini FL Baehner S Shak 2010 Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study J Clin Oncol 28 11 1829 1834 20212256 10.1200/JCO.2009.24.4798
11. J Hornberger LE Cosler GH Lyman 2005 Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer Am J Manag Care 11 5 313 324 15898220 (Pubitemid 40646936)
12. GH Lyman LE Cosler NM Kuderer J Hornberger 2007 Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies Cancer 109 6 1011 1018 17311307 10.1002/cncr.22506 (Pubitemid 46435378)
13. SH Klang A Hammerman N Liebermann N Efrat J Doberne J Hornberger 2010 Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization Value Health 13 4 381 387 20412544 10.1111/j.1524-4733.2010.00724.x
14. DT Tsoi M Inoue CM Kelly S Verma KI Pritchard 2010 Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer Oncologist 15 5 457 465 20421264 10.1634/theoncologist.2009-0275
15. M Kondo SL Hoshi H Ishiguro H Yoshibayashi M Toi 2008 Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan Breast Cancer Res Treat 112 1 175 187 18075786 10.1007/s10549-007-9842-y
16. Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K, the Japan Breast Cancer Research Group-Translational Research Group (2010) Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 116(13):3112-3118
17. H Iwata T Saeki 2006 Current practices in breast cancer treatment in Japan-a questionnaire survey Jpn J Breast Cancer 21 3 311 322
18. KP Garnock-Jones GM Keating LJ Scott 2010 Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer Drugs 70 2 215 239 20108993 10.2165/11203700-000000000-00000 1:CAS:528:DC%2BC3cXjvF2gsL8%3D
19. EB Elkin MC Weinstein EP Winer KM Kuntz SJ Schnitt JC Weeks 2004 HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis J Clin Oncol 22 5 854 863 14990641 10.1200/JCO.2004.04.158 (Pubitemid 41103597)
20. Ministry of Health, Labour, Welfare (2007) The 20th life tables. Health and Welfare Statistics Association, Tokyo
21. H Mouridsen M Gershanovich Y Sun R Perez-Carrion C Boni A Monnier J Apffelstaedt R Smith HP Sleeboom F Jaenicke A Pluzanska M Dank D Becquart PP Bapsy E Salminen R Snyder H Chaudri-Ross R Lang P Wyld A Bhatnagar 2003 Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 11 2101 2109 12775735 10.1200/JCO.2003.04.194 1:CAS:528:DC%2BD2cXpsVGqtLY%3D (Pubitemid 46606358)
22. BE Hillner TJ Smith 1991 Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model N Engl J Med 324 3 160 168 1898533 10.1056/NEJM199101173240305 1:STN:280:DyaK3M%2FnsVansA%3D%3D
23. I Smith M Procter RD Gelber S Guillaume A Feyereislova M Dowsett A Goldhirsch M Untch G Mariani J Baselga M Kaufmann D Cameron R Bell J Bergh R Coleman A Wardley N Harbeck RI Lopez P Mallmann K Gelmon N Wilcken E Wist P Sánchez Rovira MJ Piccart-Gebhart HERA study team 2007 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 9555 29 36 17208639 10.1016/S0140- 6736(07)60028-2 1:CAS:528:DC%2BD2sXit12itg%3D%3D (Pubitemid 46039831)
24. CC Earle RH Chapman CS Baker CM Bell PW Stone EA Sandberg PJ Neumann 2000 Systematic overview of cost-utility assessments in oncology J Clin Oncol 18 18 3302 3317 10986064 1:STN:280:DC%2BD3cvotlemtQ%3D%3D
25. BF Cole RD Gelber S Gelber AS Coates A Goldhirsch 2001 Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis Lancet 358 9278 277 286 11498214 10.1016/S0140-6736(01)05483-6 1:CAS:528:DC%2BD3MXlslCjsLs%3D (Pubitemid 32738966)
26. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds) (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
27. Japan Society of Clinical Oncology (2005) Kouganzai tekiseishiyou no gaidorain: nyuugan (Guideline of appropriate use of anti cancer drugs: breast cancer). Int J Clin Oncol 10(Suppl.):15-55
28. Japanese Breast Cancer Society (2006) Kagakuteki konkyo ni motozuku nyuugan shinryo gaidorain: 1 yakubutsu ryouhou 2006 nenban (Evidence-based breast cancer care guideline: 1 drug treatments 2006 version). Kanehara Shuppan, Tokyo
29. H Iwata S Nakamura M Toi E Shin N Masuda S Ohno Y Takatsuka K Hisamatsu K Yamazaki M Kusama H Kaise Y Sato K Kuroi F Akiyama H Tsuda M Kurosumi Japan Breast Cancer Research Group 2005 Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma Breast Cancer 12 2 99 103 15858439 10.2325/jbcs.12.99
30. P Papaldo G Ferretti S Di Cosimo D Giannarelli P Marolla M Lopez E Cortesi M Antimi E Terzoli P Carlini P Vici C Botti L Di Lauro G Naso C Nisticò M Mottolese F Di Filippo EM Ruggeri A Ceribelli F Cognetti 2006 Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? J Clin Oncol 24 19 3048 3055 16769988 10.1200/JCO.2005.02.9488 1:CAS:528:DC%2BD28XnslKhs74%3D (Pubitemid 46638939)
31. M Kondo SL Hoshi M Toi 2009 Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan Br J Cancer 100 2 281 290 19142182 10.1038/sj.bjc.6604869 1:CAS:528: DC%2BD1MXpsVSrsw%3D%3D
32. T Shiroiwa YK Sung T Fukuda HC Lang SC Bae K Tsutani 2010 International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19 4 422 437 19382128 10.1002/hec.1481
33. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Bryant J, Wolmark N (2004) Risk classification of breast cancer patients by the recurrence score assay: comparison to guidelines based on patient age, tumor size, and tumor grade. In: Abstracts of 27th annual San Antonio breast cancer symposium, Texas, 8-11, December 2004